aTYR PHARMA INC Proceeds from Notes Payable
aTYR PHARMA INC (ATYR) reported Proceeds from Notes Payable of $5.00 million for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2016-03-30
- aTYR PHARMA INC proceeds from notes payable for the quarter ending 2014-12-31 was $0.00.
- aTYR PHARMA INC proceeds from notes payable for the quarter ending 2014-09-30 was $0.00.
- aTYR PHARMA INC proceeds from notes payable for fiscal 2014 was $5.00M, a 0.00% change from fiscal 2013.
- aTYR PHARMA INC proceeds from notes payable for fiscal 2013 was $5.00M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $5.00M 10-K · filed 2016-03-30 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $5.00M 10-Q · filed 2015-11-10 | ||
| 2014-06-30 | $5.00M 10-Q · filed 2015-08-12 | |||
| 2013-12-31 | $5.00M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |